ACM
ORIC icon

Asymmetry Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Asymmetry Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-67,210
Closed -$2.27M – 39
2020
Q4 		$2.27M Buy
+67,210
New +$1.93M 1.04% 29

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Asymmetry Capital Management's ORIC Position: Q1 2021 in Review

Asymmetry Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q1 2021, closing a stake of 67,210 shares — an estimated $2.27M sold.

Asymmetry Capital Management first reported a position in ORIC in Q4 2020 and held it in 1 quarter. The position peaked at $2.27M in Q4 2020. 82 funds tracked by Wall St. Rank hold ORIC as of Q1 2021.

  • Asymmetry Capital Management reported no remaining Oric Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 67,210 Oric Pharmaceuticals shares in Q1 2021, an estimated $2.27M.
  • Asymmetry Capital Management first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's Oric Pharmaceuticals position peaked at $2.27M in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2021.

Based on Asymmetry Capital Management's 13F filing for Q1 2021, filed 11 May 2021.